

Today in 30 Seconds
Core idea: Three stocks offer potential value beyond the AI trade: Ashland (ASH) has a possible earnings turnaround and activist investor involvement, Central Garden & Pet (CENT) combines a modest valuation with strong free cash flow, and HCA Healthcare (HCA) benefits from ongoing demand for hospital services.
Honest catch: Ashland's recovery is not yet proven, Central Garden & Pet remains exposed to consumer spending, and HCA faces labor costs, reimbursement changes, and regulatory risks. Low valuations and earnings forecasts do not guarantee returns.
5-Year Horizon: ASH, CENT, and HCA provide exposure to materials, pet and garden products, and healthcare. Sector ETFs XLB, XLP, and XLV offer broader industry diversification, though their holdings may not include significant exposure to these specific companies.
Tip: Evaluate earnings potential, free cash flow, debt, and valuation before buying a stock simply because its price has fallen. Use sector ETFs to diversify and treat projected growth or attractive valuation ratios as possibilities, not promises.
When Nvidia dominates market headlines, attractive opportunities in other industries can easily go unnoticed. But finding value takes more than buying stocks after a sharp decline. Ashland (ASH), Central Garden & Pet (CENT), and HCA Healthcare (HCA) each present a different investment case beyond the crowded AI trade. Ashland offers potential turnaround upside as activist investors push for strategic changes. Central Garden & Pet combines recurring consumer demand with reported free cash flow of approximately $300 million annually. HCA benefits from demand for essential healthcare services and long-term demographic trends. 📊
Their valuations may deserve attention, but each company also faces risks involving execution, competition, regulation, and changing market conditions. The opportunity lies in understanding what could drive future earnings rather than reacting to headlines.
🔎 Explore the potential catalysts behind all three stocks, including Ashland’s activist pressure, Central Garden & Pet’s cash generation, and HCA’s healthcare demand. Also, see how sector ETFs such as XLB, XLP, and XLV can provide broader industry exposure without relying entirely on individual stock picks.
5-Year Horizon: AVGO in 20 seconds
$10,000 put into Broadcom on Nov 17, 2021 became about $58,530 by Nov 16, 2026 (+485.3%, price only). Investing $500 a month instead turned $30,000 into about $96,000. The catch: by Nov 16, 2026, the stock pulled back to $333.40—sitting 30.8% below its $481.57 closing high from Jun 2, 2026 (and 32.6% off its $495.00 intraday peak on Jun 3, 2026).

Why click: the full breakdown shows the month-by-month $500 plan, AVGO's lowest close along the way ($42.71 on Oct 14, 2022), and the one thing to watch after this pullback.
| ★ Sponsored by Oceans Talent | |
|
Beyond the Nvidia Selloff: 3 Undervalued Stocks With Potential for the Long Term
When a major technology stock experiences a sudden selloff, it can make the entire market feel unstable. Nvidia's leadership uncertainty and the volatility surrounding its shares have brought renewed attention to AI valuations, market concentration, and how much investors depend on a handful of mega-cap companies.
But a falling stock price does not automatically create a bargain. A company can lose value because its business is weakening, earnings are slowing, or investors are reassessing its future. The more useful question is whether the company's current price reasonably reflects its earnings potential, cash flow, and long-term business prospects.
That distinction matters when building a portfolio. Instead of chasing every dip, consider businesses with understandable revenue sources, financial strength, and valuations that leave room for future growth. Three companies stand out in this discussion: Ashland (ASH), Central Garden & Pet (CENT), and HCA Healthcare (HCA).
A Better Way to Look for Value Than Simply Buying the Dip
Nvidia's situation illustrates why market attention can shift quickly. Even a company with significant AI exposure and strong earnings expectations can experience volatility when leadership changes create uncertainty. Its stock was described in the source as trading around 17 times projected 2027 earnings, a valuation that may appear reasonable relative to its expected growth. However, investors still need to assess the management transition and whether the company's competitive position remains intact.
The bigger lesson is that a lower share price is only the starting point for research. A more complete process examines the company's operations, earnings outlook, cash generation, debt, and valuation before considering technical indicators.
Price charts can still help with timing. A stock trading below its estimated value may remain stagnant for months or years. A move above a long-standing resistance level can indicate that market interest is improving, although it does not guarantee that the business is getting stronger.
For a busy investor, this approach can prevent a common mistake: buying a stock simply because it has fallen sharply, without understanding why the market is selling it.
1. Ashland $ASH ( ▼ 1.09% ): A Potential Turnaround With Activist Investor Pressure
Ashland is not a typical headline-grabbing technology company. It produces specialty additives and ingredients used in food, beauty products, life sciences, and other industries. Its business is tied to materials and ingredients that serve multiple markets, giving investors exposure beyond the crowded AI trade.
The attraction is its potential earnings recovery. The estimates discussed in the source point to earnings growth of approximately 28% in the fiscal year ending September 2027, followed by another 32% over the subsequent two years. At roughly 18 times projected 2027 earnings, the valuation could look attractive if the company delivers that improvement.
The PEG ratio helps explain the value argument. Dividing its forward price-to-earnings multiple of 18 by expected earnings growth of 28% produces a ratio below 1. This is often considered attractive, although the metric is only useful when earnings forecasts are realistic. Ashland has struggled in previous years, so the projected recovery still needs to be demonstrated through actual results.
There is another possible catalyst: activist investors. These investors have pushed for changes, including the addition of two board members, while the board considers strategic alternatives. That could involve selling the company, separating part of the business, or making operational changes to improve performance.
The source compares Ashland with a similar materials business that was sold for approximately 13 times EBITDA. Applying that multiple to Ashland's current guidance produced an illustrative value of $118 per share, compared with the cited share price of $76. This is not a price target or a guaranteed takeover valuation. The businesses are not identical, and an actual transaction could command a different multiple.
Short interest adds another layer of uncertainty. Approximately 11% of Ashland's public float was reportedly sold short. If the stock rises and short sellers rush to buy shares to close their positions, the additional demand could amplify the move. But high short interest can also signal that investors have serious concerns about the business.
The ETF angle: Ashland's specialty-chemicals exposure is different from the technology-heavy holdings found in many AI and semiconductor ETFs. Investors looking for broader exposure to materials companies can research materials-sector funds such as the Materials Select Sector SPDR Fund (XLB). However, a sector ETF will not necessarily capture Ashland's specific activist-investor opportunity, and its current holdings should be checked before investing.
2. Central Garden & Pet $CENT ( ▼ 0.34% ): A Business Built Around Continuing Pet Care Demand
Central Garden & Pet operates in the pet and garden markets, supplying products that support pet ownership, lawn care, and gardening. Its appeal comes from a recurring consumer need: people may reduce discretionary spending during difficult economic periods, but many are unlikely to stop caring for their pets.
That does not make the business recession-proof. Pet owners may trade down from premium products to less expensive alternatives, and demand can still be affected by household budgets. However, the emotional importance of pets may help support spending on essential food, supplies, and care products.
The valuation is a major part of the investment case. The source cites approximately 14 times forward earnings, compared with expected earnings growth of 27% over four years. Its price-to-sales ratio is around 1, while its price-to-cash-flow ratio is below 8, both described as lower than relevant sector comparisons.
Cash generation is particularly important here. Central Garden & Pet reportedly produces approximately $300 million in annual free cash flow and has maintained a relatively stable debt level while increasing its cash balance. Positive free cash flow gives a company more flexibility to invest in operations, manage debt, and potentially return capital to shareholders.
The share price has also spent roughly five to six years trading within a broad range. The source identifies $45 as an important resistance level. A sustained move above it could suggest improving investor demand, with $60 presented as a possible 12-month scenario. That outcome depends on the company delivering its expected performance and the market assigning it a higher valuation; it is not a guaranteed result.
For investors, the important distinction is that Central Garden & Pet does not need explosive growth to become interesting. A business with steady cash generation, a manageable balance sheet, and a reasonable valuation can offer a different kind of opportunity from high-growth technology stocks.
The ETF angle: Investors can explore consumer-staples ETFs for exposure to businesses that sell recurring household products. The Consumer Staples Select Sector SPDR Fund (XLP) is one example, although its portfolio is concentrated in large consumer-staples companies and may not provide meaningful exposure to Central Garden & Pet. Check its current holdings rather than assuming the fund owns the stock.
3. HCA Healthcare $HCA ( ▼ 1.88% ): Healthcare Demand That Does Not Depend on a Strong Economy
HCA Healthcare operates one of the largest hospital networks in the United States. Its business benefits from a fundamental reality: medical needs do not disappear when economic conditions weaken. People still require emergency treatment, surgeries, hospital care, and other essential medical services.
HCA also has significant exposure to Texas and Florida, two states that have experienced population growth. Florida's older population is particularly relevant because healthcare utilization generally increases with age. A growing population can support demand for hospital services, although local competition, labor costs, reimbursement rates, and regulatory changes remain important factors.
The valuation case rests on long-term earnings expectations. The source cites a price-to-earnings ratio of approximately 17, below the healthcare sector median of around 20. Earnings are projected to more than triple over the next decade, although that is a long-range estimate and should not be treated as a certainty.
The near-term outlook is more measured. Earnings growth is expected to remain in the single digits in 2026 and 2027, with faster growth projected from 2028 onward. Those forecasts may change as operating costs, patient volumes, reimbursement policies, and healthcare regulations evolve.
Government policy is another consideration. Changes to Medicaid funding can affect hospital finances, while proposals such as Medicare for All could significantly reshape the healthcare system. The source discusses potential political support for hospitals, but policy outcomes are uncertain and should not be treated as dependable catalysts.
HCA's long-term share-price history is also notable. The source describes the stock as having gained roughly 30 times over approximately 15 years, while trading around 10% below its all-time high at the time of the discussion. That history demonstrates the company's past performance, not a guarantee of future returns.
HCA may appeal to investors seeking exposure to an established healthcare operator rather than a speculative biotech company. Its scale can provide advantages in purchasing, operations, and market presence, but hospitals remain capital-intensive businesses with substantial staffing and regulatory demands.
The ETF angle: Healthcare ETFs offer a way to diversify exposure across hospitals, pharmaceutical companies, medical-device makers, and other healthcare businesses. The Health Care Select Sector SPDR Fund (XLV) is one broad sector option. Investors should compare its holdings and concentration with HCA's business exposure, since a healthcare ETF may be dominated by pharmaceutical and biotechnology companies rather than hospital operators.
What These Three Stocks Offer Beyond the AI Trade
Ashland, Central Garden & Pet, and HCA Healthcare operate in very different industries, but they share an important characteristic: their investment cases are based on business fundamentals rather than excitement around artificial intelligence.
Ashland offers a possible turnaround supported by activist pressure, but its recovery remains unproven. Central Garden & Pet combines a relatively modest valuation with strong reported free cash flow, although consumer spending can still affect demand. HCA provides exposure to essential healthcare services and long-term demographic demand, while remaining sensitive to reimbursement policy, labor costs, and regulation.
These are not risk-free investments, and a low valuation alone does not make any company a suitable purchase. The strongest opportunity is one where the business can deliver on its earnings expectations, maintain financial flexibility, and justify its valuation over time.
How ETFs Can Help Build a More Balanced Portfolio
For investors who do not have the time to research and monitor individual companies, ETFs can provide a more diversified way to access these industries. XLB offers materials-sector exposure, XLP focuses on consumer staples, and XLV provides healthcare exposure. Each fund spreads investment across multiple companies, reducing dependence on the performance of a single stock.
However, diversification does not eliminate market risk. Sector ETFs can still decline when their industries face pressure, and their holdings may not include the specific companies discussed here. Before investing, review each fund's current holdings, sector weights, expense ratio, and overlap with existing positions.
A portfolio built around broad-market ETFs can also use these sector funds as smaller allocations rather than replacing diversified core investments. This can help avoid concentrating too much capital in a single industry or investment theme.
The Bigger Opportunity Is Buying Businesses, Not Headlines
Market volatility can make every dip look urgent. But a disciplined investor does not need to react to every headline or chase whichever stock has fallen the most. The better approach is to understand what a business earns, what could improve its future earnings, how much cash it generates, and whether its current valuation offers a reasonable margin of safety.
Ashland, Central Garden & Pet, and HCA Healthcare provide three different examples of how value can emerge outside the technology stocks dominating market attention. Their potential depends on execution, financial performance, and reasonable expectations—not simply on how far their shares have fallen.
Investing Wize Tip: Build a watchlist around business quality, earnings growth, cash flow, and valuation before looking for an entry point; use sector ETFs such as XLB, XLP, and XLV to broaden exposure, and avoid treating a low share price or an attractive PEG ratio as proof that a stock is cheap.
5-Year Horizon $AVGO ( ▲ 1.35% ): AI Infrastructure Surge Meets a Sharp Pullback in Broadcom
Imagine setting aside $500 a month for $AVGO ( ▲ 1.35% ) for five years, buying a fixed dollar amount on a schedule, a method called dollar-cost averaging. In our example the buy happens on the first trading day on or after the 9th of each month, from Nov 17, 2021 through Oct 9, 2026 (the first buy lands on the start date, Nov 17, 2021, because Nov 9 had already passed): 60 buys, $30,000 in total.
AVGO closed at $56.96 on Nov 17, 2021 (adjusted for its 10-for-1 stock split) and at $333.40 on Nov 16, 2026, a price gain of about 485.3%, or roughly 42.4% a year compounded (the steady yearly rate that would give the same total gain). In that example the $30,000 invested via dollar-cost averaging would have been worth about $96,000 at the Nov 16, 2026 close (about 3.2 times the money put in), and a single $10,000 lump sum invested on Nov 17, 2021 would have become about $58,530. Price only: no dividends, fees or taxes, and these are examples, not forecasts.
The highest intraday peak of the past 52 weeks was $495.00 on Jun 3, 2026 (with a closing high of $481.57 on Jun 2, 2026), so the Nov 16, 2026 close sat about 30.8% below that closing high and 32.6% below the intraday peak. The lowest close of the five years was $42.71 on Oct 14, 2022, about 25.0% below the $56.96 start.
Caution: past pace rarely continues. Broadcom's Sep 2, 2026 release for the fiscal third quarter ended Aug 2, 2026 showed net revenue surging 86% year-over-year to $29.6 billion and GAAP operating income jumping 171% to $16.0 billion, alongside fourth-quarter revenue guidance of approximately $34.8 billion. Despite explosive AI and semiconductor demand, the stock retreated from its Jun 3, 2026 intraday peak of $495.00 down toward a 52-week intraday low of $289.77 on Nov 6, 2026 before settling at $333.40 on Nov 16, 2026, a reminder that even market-leading tech giants experience steep price corrections after massive runs.
Follow the discussion
Follow $AVGO ( ▲ 1.35% ) on StockTwits: today's 5-Year Horizon, about +485.3% from Nov 17, 2021 to Nov 16, 2026.
Why click: see what other investors are saying about AVGO right now, and follow the ticker so its next big move shows up in your feed.
Quick question
Tell us if this shorter format works: one question, takes a few seconds.
How would you rate today's newsletter?
Hit reply and tell me what you'd watch after AVGO's 30.8% pullback from its $481.57 closing high. I read every answer.
That's it
Thank you for taking the time to read today’s email.
This newsletter is for informational purposes only and should not be considered financial advice. Please consult with a financial advisor before making any investment decisions.
